Bufalin Enhances the Cytotoxity of Human Multiple Myeloma Cells H929 to AKT Inhibitor MK2206: The Role of Protein AKT Phosphorylation

  • He Huang
  • Xiao-ji Lin
  • Ying Lin
  • Ron-xin Yao
  • Mu-qing He
Original Article


This study was purposed to investigate bufalin combined with AKT inhibitor MK2206 on growth inhibition and apoptosis of multiple myeloma cell line H929. CCK-8 assay and Annexin/PI staining were used to access the effects of bufalin and MK2206 in single or in combination, on inhibition of proliferation and induction of apoptosis in H929 cells. The apoptotic cells markedly increased after treated with nM bufalin and μM MK2206, including caspase3 and PARP1 proteins activated. The difference was statistically significant (P < 0.05) when compared with these drugs in single use. The apoptosis associated proteins and AKT/p-AKT proteins were determined by Western blots. We confirmed that AKT performed contradictory results in H929 with the two agents, and concluded p-AKT was vital in the synergy. The underlying mechanisms warrant further investigation.


Bufalin AKT p-AKT Multiple myeloma 



This study was funded by Wenzhou Municipal Science and Technology Bureau (CN) (Grant Number 2014s0267).

Compliance with Ethical Standards

Conflict of interest

All authors declare there is no conflict of interest.

Ethical Approval

This article does not contain any studies with human participants or animals performed by any of the authors.


  1. 1.
    Kumar S, Paiva B, Anderson KC et al (2016) International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol 17(8):e328–e346CrossRefPubMedGoogle Scholar
  2. 2.
    Hsu J, Shi Y, Krajewski S et al (2001) The AKT kinase is activated in multiple myeloma tumor cells. Blood 98(9):2853–2855CrossRefPubMedGoogle Scholar
  3. 3.
    Keane NA, Glavey SV, Krawczyk J et al (2014) AKT as a therapeutic target in multiple myeloma. Expert Opin Ther Targets 18(8):897–915CrossRefPubMedGoogle Scholar
  4. 4.
    Toker A, Yoeli-Lerner M (2006) Akt signaling and cancer: surviving but not moving on. Cancer Res 66(8):3963–3966CrossRefPubMedGoogle Scholar
  5. 5.
    Song G, Ouyang G, Bao S (2005) The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med 9(1):59–71CrossRefPubMedGoogle Scholar
  6. 6.
    Hirai H, Sootome H, Nakatsuru Y et al (2010) MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 9(7):1956–1967CrossRefPubMedGoogle Scholar
  7. 7.
    Ramakrishnan V, Kimlinger T, Haug J et al (2012) Anti-myeloma activity of Akt inhibition is linked to the activation status of PI3K/Akt and MEK/ERK pathway. PLoS ONE 7(11):e50005CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Huang H, Cao Y, Wei W et al (2013) Targeting poly (ADP-ribose) polymerase partially contributes to bufalin-induced cell death in multiple myeloma cells. PLoS ONE 8(6):e66130CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Zhang LS, Nakaya K, Yoshida T et al (1991) Bufalin as a potent inducer of differentiation of human myeloid leukemia cells. Biochem Biophys Res Commun 178(2):686–693CrossRefPubMedGoogle Scholar
  10. 10.
    Zhang L, Nakaya K, Yoshida T et al (1992) Induction by bufalin of differentiation of human leukemia cells HL60, U937, and ML1 toward macrophage/monocyte-like cells and its potent synergistic effect on the differentiation of human leukemia cells in combination with other inducers. Cancer Res 52(17):4634–4641PubMedGoogle Scholar
  11. 11.
    Chen A, Yu J, Zhang L, Sun Y et al (2009) Microarray and biochemical analysis of bufalin-induced apoptosis of HL-60 Cells. Biotechnol Lett 31(4):487–494CrossRefPubMedGoogle Scholar
  12. 12.
    Yeh JY, Huang WJ, Kan SF et al (2003) Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54(2):112–124CrossRefPubMedGoogle Scholar
  13. 13.
    Takai N, Ueda T, Nishida M et al (2008) Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med 21(5):637–643PubMedGoogle Scholar
  14. 14.
    Li D, Qu X, Hou K et al (2009) PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs 20(20):59–64CrossRefPubMedGoogle Scholar
  15. 15.
    Meng Z, Yang P, Shen Y et al (2009) Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 115(22):5309–5318CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Qi F, Li A, Zhao L et al (2010) Cinobufacini, an aqueous extract from Bufo bufo gargarizans Cantor, induces apoptosis through a mitochondria-mediated pathway in human hepatocellular carcinoma cells. J Ethnopharmacol 128(3):654–661CrossRefPubMedGoogle Scholar
  17. 17.
    Takai N, Kira N, Ishii T et al (2012) Bufalin, a traditional oriental medicine, induces apoptosis in human cancer cells. Asian Pac J Cancer Prev 13(1):399–402CrossRefPubMedGoogle Scholar
  18. 18.
    Arnaud-Batista FJ, Costa GT, Oliveira IM et al (2012) Natriuretic effect of bufalin in isolated rat kidneys involves activation of the Na+-K+-ATPase-Src kinase pathway. Am J Physiol Renal Physiol 302(8):F959–F966CrossRefPubMedGoogle Scholar
  19. 19.
    Zhao Y, Pu JX, Huang SX et al (2009) ent-Kaurane diterpenoids from Isodon pharicus. J Nat Prod 72(6):988–993CrossRefPubMedGoogle Scholar
  20. 20.
    Yin PH, Liu X, Qiu YY et al (2012) Anti-tumor activity and apoptosis-regulation mechanisms of bufalin in various cancers: new hope for cancer patients. Asian Pac J Cancer Prev 13(11):5339–5343CrossRefPubMedGoogle Scholar
  21. 21.
    Xu N, Lao Y, Zhang Y et al (2012) Akt: a double-edged sword in cell proliferation and genome stability. J Oncol 2012:951724CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Demel HR, Feuerecker B, Piontek G et al (2015) Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells. Am J Cancer Res 5(5):1649–1664PubMedPubMedCentralGoogle Scholar

Copyright information

© Indian Society of Haematology & Transfusion Medicine 2017

Authors and Affiliations

  • He Huang
    • 1
  • Xiao-ji Lin
    • 1
  • Ying Lin
    • 1
  • Ron-xin Yao
    • 1
  • Mu-qing He
    • 1
  1. 1.Department of HematologyThe 2nd Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical UniversityWenzhouPeople’s Republic of China

Personalised recommendations